Founded in 2010, the company is headquartered in Singapore and has offices in Taiwan and China. ASLAN is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in ...
After hours: March 20 at 7:08:38 PM EDT Loading Chart for TMUS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback